6-氯萘-1-磺酰氯 | 102153-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-氯萘-1-磺酰氯
• 英文名称: 6-chloronaphthalene-1-sulfonyl chloride
• 英文别名: 6-Chlor-naphthalin-1-sulfochlorid；6-Chloronaphthalenesulphonyl chloride；6-chloronaphthylsulfonyl chloride；6-Chlor-naphthalin-1-sulfonylchlorid；6-chloronaphth-2-ylsulfonyl chloride
• CAS: 102153-61-7
• 化学式: C₁₀H₆Cl₂O₂S
• 分子量: 261.128
• InChiKey: ZHEYVXCFYIWQOM-UHFFFAOYSA-N

物化性质

• 沸点：
  375.4±17.0 °C(Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-氯萘-1-磺酰氯 生成 1,6-二氯萘
  参考文献：
  名称：

  Armstrong; Wynne, Chemical news and journal of industrial science, 1895, vol. 71, p. 253

  摘要：

  DOI：
• 作为产物：
  描述：

  6-chloro-naphthalene-1-sulfonic acid 在 氯化亚砜 作用下， 生成 6-氯萘-1-磺酰氯
  参考文献：
  名称：

  芳香反应性。第三十七部分 取代的1-和2-三氢萘的降解

  摘要：

  已经测量了一系列X-1-和X-2-tritionaphthalenes在三氟乙酸中的降解速率。相对于母体1-或-2-三苯并萘的比率为70·0°（某些情况下，显示为斜体，是通过在其他温度下的外推法得出的），其比率如下：（a）1-三化合物; （X =）2-Me 300；3Me 2·75；4-我83 ; 5Me 2·18；6-Me 1·31；7-Me 2·90；8-我1·53; 2-OMe 2·2 ×10 4；4-OMe 8600 ; 5-OMe 3·87；4相15·9；2-F 1·71；4-F 4·6；5-F 0·043；8-F 0·053；2-氯0·26；3-氯0·0023；4-Cl 0·265；5-氯0·028；6-氯0·032；7-CI 0·138；8-CI 0·043；2-溴0·165；4-溴0·135; 5-溴0·025；8-溴0·047；2-I 0·32；4-I〜0 ·18；8-I

  DOI：

  10.1039/j29680001112

文献信息

• Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
  申请人：——

  公开号：US20040006062A1

  公开（公告）日：2004-01-08

  The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了Formula I中的磺酰氨基戊内内酰胺及其衍生物，或其药用盐形式，其中环G是单环或双环碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶抑制剂，特别是对凝血因子Xa的抑制剂。
• [EN] N-(1-(2,3-DIHYDRO-1H-INDEN-5YL) -2-OXO-3-PYRROLIDINYL) -SULFONAMIDE DERIVATIVES FOR USE AS FACTOR XA INHIBITORS<br/>[FR] DERIVES DE N-(1-(2,3-DIHYDRO-1H-INDEN-5YL) -2-OXO-3-PYRROLIDINYL)-SULFONAMIDE UTILES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：GLAXO GROUP LTD

  公开号：WO2006027186A1

  公开（公告）日：2006-03-16

  The invention relates to at least one chemical entity chosen from compounds of formula (I): wherein: R1 represents a group selected from (II): each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, alk represents alkylene or alkenylene, T represents S, O or NH; R2 represents hydrogen, -C1-6alkyl, - C1-3alkyl CONRaRb, - C1-3alkyl CO2 C1-4alkyl, -CO2 C1-4alkyl or - C1-3alkyl CO2H; Ra and Rb independently represent hydrogen, - C1-6alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N and S, optionally substituted by C1-4alkyl, and optionally the S heteroatom is substituted by O, i.e. represents S(O)n; n represents 0-2; X represents an optional substituent on the indane ring selected from: halogen, - C1-4alkyl, -C2-4alkenyl and -CF3; Y represents a group -(CH2)mNRcRd substituted on the non-aromatic portion of the indane ring; Rc and Rd independently represent hydrogen, - C1-6alkyl, - C1-4alkylOH, or together with the N atom to which they are bonded form a 4-, 5-, 6- or 7- membered non-aromatic heterocyclic ring, the 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, and the 4-, 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally substituted by C1-4alkyl or halogen; m represents 0-2; and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  该发明涉及至少一种化学实体，选择自化合物的公式（I）：其中：R1代表从（II）中选择的基团：每个环可选地含有进一步的杂原子N，Z代表可选的取代卤素，alk代表烷基或烯基，T代表S、O或NH；R2代表氢、-C1-6烷基、-C1-3烷基CONRaRb、-C1-3烷基CO2C1-4烷基、-CO2C1-4烷基或-C1-3烷基CO2H；Ra和Rb独立地代表氢、-C1-6烷基，或者与它们连接的N原子一起形成一个5、6或7-成员非芳香杂环，可选地含有另一个从O、N和S中选择的杂原子，可选地被C1-4烷基取代，且可选地S杂原子被O取代，即表示S（O）n；n代表0-2；X代表在茚环上的可选取代基，选择自：卤素、-C1-4烷基、-C2-4烯基和-CF3；Y代表取代在茚环非芳香部分上的群-(CH2)mNRcRd；Rc和Rd独立地代表氢、-C1-6烷基、-C1-4烷基OH，或者与它们连接的N原子一起形成一个4、5、6或7-成员非芳香杂环，5、6或7-成员非芳香杂环可选地含有另一个从O、N或S中选择的杂原子，4、5、6或7-成员非芳香杂环可选地被C1-4烷基或卤素取代；m代表0-2；及其药学上可接受的衍生物。该发明还涉及制备公式（I）化合物的方法，含有公式（I）化合物的药物组合物以及在医学上使用公式（I）化合物，特别是在改善适应于Xa因子抑制剂的临床病况方面。
• Heterocycle derivatives which inhibit factor Xa
  申请人：Zeneca Limited

  公开号：US06300330B1

  公开（公告）日：2001-10-09

  The invention relates to heterocyclic derivatives of the formula (I): A—B—X1—T1(R2)—L1—T2(R3)—X2—Q or pharmaceutically acceptable salts thereof, which possess antithrombotic and anticoagulant properties due to their inhibition of Factor Xa and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

  本发明涉及公式（I）的杂环衍生物：A-B-X1-T1（R2）-L1-T2（R3）-X2-Q或其药学上可接受的盐，由于它们抑制因子Xa而具有抗血栓和抗凝作用，因此在人类或动物的治疗方法中有用。本发明还涉及制备杂环衍生物的方法，含有它们的制药组合物以及它们在制造用于产生抗血栓或抗凝效果的药物中的用途。
• Heterocyclic derivatives
  申请人：——

  公开号：US20030195203A1

  公开（公告）日：2003-10-16

  The invention relates to heterocyclic derivatives of formula (I) A—B—X 1 —T 1 (R 2 )—L 1 —T 2 (R 3 )—X 2 —Q  (I) or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

  本发明涉及公式(I)A-B-X1-T1(R2)-L1-T2(R3)-X2-Q的杂环衍生物或其药学上可接受的盐，具有抗血栓和抗凝血特性，因此在人类或动物的治疗方法中有用。本发明还涉及制备这些杂环衍生物的过程，含有它们的制药组合物以及它们用于制造用于产生抗血栓或抗凝血效应的药物的用途。
• N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors
  申请人：Harling David John

  公开号：US20070249705A1

  公开（公告）日：2007-10-25

  The invention relates to at least one chemical entity chosen from compounds of formula (I): and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及至少一种化学实体，所选实体为式（I）化合物和其药学上可接受的衍生物。本发明还涉及制备式（I）化合物的方法，含有式（I）化合物的药物组合物以及将式（I）化合物用于医学，特别是用于改善适应于Xa因子抑制剂的临床状况。